Collaborative Agreements (Details) (USD $)	3 Months Ended		1 Months Ended	3 Months Ended		41 Months Ended		1 Months Ended	41 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	May 31, 2000 Roche Development, Manufacturing and Commercialization Kadcyla	Sep. 30, 2013 Roche Development, Manufacturing and Commercialization Kadcyla	May 31, 2000 Roche Development, Manufacturing and Commercialization Kadcyla Maximum	Sep. 30, 2013 Roche Development, Manufacturing and Commercialization Kadcyla Development milestones	May 31, 2000 Roche Development, Manufacturing and Commercialization Kadcyla Development milestones	Sep. 30, 2013 Roche Development, Manufacturing and Commercialization Kadcyla Regulatory milestones	Sep. 30, 2013 Roche Development, Manufacturing and Commercialization Kadcyla Regulatory milestones	May 31, 2000 Roche Development, Manufacturing and Commercialization Kadcyla Regulatory milestones
Collaborative Agreements disclosures
Payments received under collaboration agreement			$ 2,000,000			$ 13,500,000			$ 15,500,000
Potential milestone payment receivable					44,000,000		13,500,000			30,500,000
Amount of arrangement consideration included in license and milestone fees	13,167,000	933,000						5,000,000
Period in arrears to receive royalty reports and payments related to sales of Kadcyla				3 months
Royalties on net sales of Kadcyla	$ 2,053,000			$ 2,100,000